Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.26 Analyst target: $31.85 Upside: 210.43%
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.